These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
332 related articles for article (PubMed ID: 36049147)
1. Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated Ascierto PA; Mandalà M; Ferrucci PF; Guidoboni M; Rutkowski P; Ferraresi V; Arance A; Guida M; Maiello E; Gogas H; Richtig E; Fierro MT; Lebbè C; Helgadottir H; Queirolo P; Spagnolo F; Tucci M; Del Vecchio M; Gonzales Cao M; Minisini AM; De Placido S; Sanmamed MF; Mallardo D; Curvietto M; Melero I; Palmieri G; Grimaldi AM; Giannarelli D; Dummer R; Chiarion Sileni V J Clin Oncol; 2023 Jan; 41(2):212-221. PubMed ID: 36049147 [TBL] [Abstract][Full Text] [Related]
2. Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial. Dummer R; Ascierto PA; Gogas HJ; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; Chiarion Sileni V; Dutriaux C; de Groot JWB; Yamazaki N; Loquai C; Moutouh-de Parseval LA; Pickard MD; Sandor V; Robert C; Flaherty KT Lancet Oncol; 2018 Oct; 19(10):1315-1327. PubMed ID: 30219628 [TBL] [Abstract][Full Text] [Related]
3. Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial. Ascierto PA; Casula M; Bulgarelli J; Pisano M; Piccinini C; Piccin L; Cossu A; Mandalà M; Ferrucci PF; Guidoboni M; Rutkowski P; Ferraresi V; Arance A; Guida M; Maiello E; Gogas H; Richtig E; Fierro MT; Lebbe C; Helgadottir H; Queirolo P; Spagnolo F; Tucci M; Del Vecchio M; Cao MG; Minisini AM; De Placido S; Sanmamed MF; Mallardo D; Paone M; Vitale MG; Melero I; Grimaldi AM; Giannarelli D; Dummer R; Sileni VC; Palmieri G Nat Commun; 2024 Jan; 15(1):146. PubMed ID: 38167503 [TBL] [Abstract][Full Text] [Related]
4. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. Dummer R; Ascierto PA; Gogas HJ; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; Chiarion-Sileni V; Dutriaux C; de Groot JWB; Yamazaki N; Loquai C; Moutouh-de Parseval LA; Pickard MD; Sandor V; Robert C; Flaherty KT Lancet Oncol; 2018 May; 19(5):603-615. PubMed ID: 29573941 [TBL] [Abstract][Full Text] [Related]
5. COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600E/K-mutant melanoma. Schadendorf D; Dummer R; Flaherty KT; Robert C; Arance A; de Groot JWB; Garbe C; Gogas HJ; Gutzmer R; Krajsová I; Liszkay G; Loquai C; Mandalà M; Yamazaki N; Queirolo P; Guenzel C; Polli A; Thakur M; di Pietro A; Ascierto PA Eur J Cancer; 2024 Jun; 204():114073. PubMed ID: 38723373 [TBL] [Abstract][Full Text] [Related]
6. COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With Dummer R; Flaherty KT; Robert C; Arance A; de Groot JWB; Garbe C; Gogas HJ; Gutzmer R; Krajsová I; Liszkay G; Loquai C; Mandalà M; Schadendorf D; Yamazaki N; di Pietro A; Cantey-Kiser J; Edwards M; Ascierto PA J Clin Oncol; 2022 Dec; 40(36):4178-4188. PubMed ID: 35862871 [TBL] [Abstract][Full Text] [Related]
7. Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced Atkins MB; Lee SJ; Chmielowski B; Tarhini AA; Cohen GI; Truong TG; Moon HH; Davar D; O'Rourke M; Stephenson JJ; Curti BD; Urba WJ; Brell JM; Funchain P; Kendra KL; Ikeguchi AP; Jaslowski A; Bane CL; Taylor MA; Bajaj M; Conry RM; Ellis RJ; Logan TF; Laudi N; Sosman JA; Crockett DG; Pecora AL; Okazaki IJ; Reganti S; Chandra S; Guild S; Chen HX; Streicher HZ; Wolchok JD; Ribas A; Kirkwood JM J Clin Oncol; 2023 Jan; 41(2):186-197. PubMed ID: 36166727 [TBL] [Abstract][Full Text] [Related]
8. Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With Riely GJ; Smit EF; Ahn MJ; Felip E; Ramalingam SS; Tsao A; Johnson M; Gelsomino F; Esper R; Nadal E; Offin M; Provencio M; Clarke J; Hussain M; Otterson GA; Dagogo-Jack I; Goldman JW; Morgensztern D; Alcasid A; Usari T; Wissel P; Wilner K; Pathan N; Tonkovyd S; Johnson BE J Clin Oncol; 2023 Jul; 41(21):3700-3711. PubMed ID: 37270692 [TBL] [Abstract][Full Text] [Related]
9. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. Hodi FS; Chiarion-Sileni V; Gonzalez R; Grob JJ; Rutkowski P; Cowey CL; Lao CD; Schadendorf D; Wagstaff J; Dummer R; Ferrucci PF; Smylie M; Hill A; Hogg D; Marquez-Rodas I; Jiang J; Rizzo J; Larkin J; Wolchok JD Lancet Oncol; 2018 Nov; 19(11):1480-1492. PubMed ID: 30361170 [TBL] [Abstract][Full Text] [Related]
10. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. Hodi FS; Chesney J; Pavlick AC; Robert C; Grossmann KF; McDermott DF; Linette GP; Meyer N; Giguere JK; Agarwala SS; Shaheen M; Ernstoff MS; Minor DR; Salama AK; Taylor MH; Ott PA; Horak C; Gagnier P; Jiang J; Wolchok JD; Postow MA Lancet Oncol; 2016 Nov; 17(11):1558-1568. PubMed ID: 27622997 [TBL] [Abstract][Full Text] [Related]
11. Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management. Gogas HJ; Flaherty KT; Dummer R; Ascierto PA; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; Sileni VC; Dutriaux C; de Groot JWB; Yamazaki N; Loquai C; Gollerkeri A; Pickard MD; Robert C Eur J Cancer; 2019 Sep; 119():97-106. PubMed ID: 31437754 [TBL] [Abstract][Full Text] [Related]
12. Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma. Ascierto PA; Dummer R; Gogas HJ; Flaherty KT; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; de Groot JWB; Loquai C; Gollerkeri A; Pickard MD; Robert C Eur J Cancer; 2020 Feb; 126():33-44. PubMed ID: 31901705 [TBL] [Abstract][Full Text] [Related]
13. A matching-adjusted indirect comparison of combination nivolumab plus ipilimumab with BRAF plus MEK inhibitors for the treatment of BRAF-mutant advanced melanoma Tarhini AA; Toor K; Chan K; McDermott DF; Mohr P; Larkin J; Hodi FS; Lee CH; Rizzo JI; Johnson H; Moshyk A; Rao S; Kotapati S; Atkins MB ESMO Open; 2021 Apr; 6(2):100050. PubMed ID: 33556898 [TBL] [Abstract][Full Text] [Related]
14. Binimetinib in combination with nivolumab or nivolumab and ipilimumab in patients with previously treated microsatellite-stable metastatic colorectal cancer with RAS mutations in an open-label phase 1b/2 study. Elez E; Cubillo A; Alfonso PG; Middleton MR; Chau I; Alkuzweny B; Alcasid A; Zhang X; Van Cutsem E BMC Cancer; 2024 Apr; 24(1):446. PubMed ID: 38600471 [TBL] [Abstract][Full Text] [Related]
15. ANCHOR CRC: Results From a Single-Arm, Phase II Study of Encorafenib Plus Binimetinib and Cetuximab in Previously Untreated Van Cutsem E; Taieb J; Yaeger R; Yoshino T; Grothey A; Maiello E; Elez E; Dekervel J; Ross P; Ruiz-Casado A; Graham J; Kato T; Ruffinelli JC; André T; Carrière Roussel E; Klauck I; Groc M; Vedovato JC; Tabernero J J Clin Oncol; 2023 May; 41(14):2628-2637. PubMed ID: 36763936 [TBL] [Abstract][Full Text] [Related]
16. Clinical Predictors of Survival in Patients With BRAFV600-Mutated Metastatic Melanoma Treated With Combined BRAF and MEK Inhibitors After Immune Checkpoint Inhibitors. Kahn AM; Perry CJ; Etts K; Kluger H; Sznol M Oncologist; 2024 Apr; 29(4):e507-e513. PubMed ID: 37971411 [TBL] [Abstract][Full Text] [Related]
17. Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma. Wolchok JD; Chiarion-Sileni V; Gonzalez R; Grob JJ; Rutkowski P; Lao CD; Cowey CL; Schadendorf D; Wagstaff J; Dummer R; Ferrucci PF; Smylie M; Butler MO; Hill A; Márquez-Rodas I; Haanen JBAG; Guidoboni M; Maio M; Schöffski P; Carlino MS; Lebbé C; McArthur G; Ascierto PA; Daniels GA; Long GV; Bas T; Ritchings C; Larkin J; Hodi FS J Clin Oncol; 2022 Jan; 40(2):127-137. PubMed ID: 34818112 [TBL] [Abstract][Full Text] [Related]
18. COLUMBUS 5-year update: a randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF. Dummer R; Flaherty KT; Robert C; Arance A; B de Groot JW; Garbe C; Gogas HJ; Gutzmer R; Krajsová I; Liszkay G; Loquai C; Mandalà M; Schadendorf D; Yamazaki N; Pietro AD; Cantey-Kiser J; Edwards M; Ascierto PA Future Oncol; 2023 May; 19(16):1091-1098. PubMed ID: 37309702 [TBL] [Abstract][Full Text] [Related]
19. Encorafenib plus binimetinib in patients with Riely GJ; Ahn MJ; Felip E; Ramalingam SS; Smit EF; Tsao AS; Alcasid A; Usari T; Wissel PS; Wilner KD; Johnson BE Future Oncol; 2022 Mar; 18(7):781-791. PubMed ID: 34918546 [TBL] [Abstract][Full Text] [Related]
20. Encorafenib in combination with binimetinib for unresectable or metastatic melanoma with BRAF mutations. Trojaniello C; Festino L; Vanella V; Ascierto PA Expert Rev Clin Pharmacol; 2019 Mar; 12(3):259-266. PubMed ID: 30652516 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]